On Tuesday, Shares of Apple Inc. (NASDAQ:AAPL), lost -0.09% to $130.07.
Apple, updated the 15-inch MacBook Pro® with Retina® display with the new Force Touch trackpad, faster flash storage, longer battery life and faster discrete graphics, delivering even more performance and capabilities to the MacBook Pro line. Apple also recently introduced a new $1,999 configuration of the 27-inch iMac® with Retina 5K display featuring a breathtaking 14.7 million pixel display, quad-core processors and AMD graphics, and lowered the price of the top-end iMac with Retina 5K display to $2,299.
The updated 15-inch MacBook Pro features the amazing Force Touch trackpad that brings a new dimension of interactivity to the Mac®. With built-in force sensors and a Taptic Engine that delivers haptic feedback, the Force Touch trackpad allows you to click anywhere with a uniform feel and customize the amount of pressure needed to register each click. The new trackpad supports a range of new gestures, counting the new Force click, and APIs are accessible for third-party developers to incorporate Force Touch capabilities into their apps. The updated 15-inch MacBook Pro with Retina display also features up to 2.5 times faster flash storage than the previous generation, with throughput up to 2GBps, and offers an additional hour of battery life, with up to 9 hours of wireless web browsing and up to 9 hours of iTunes® movie playback. In addition, MacBook Pro with Retina display discrete graphics deliver up to 80 percent faster performance using new AMD Radeon R9 M370X graphics for editing video in Final Cut Pro® X, rendering 3D images in pro graphics apps or playing high-resolution games.
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
Shares of Fifth Third Bancorp (NASDAQ:FITB), inclined 2.05% to $20.94, during its last trading session, after analysts at Oppenheimer upgraded the company to “outperform” from “market perform” with a price target of $25.
The analyst action comes after the company posted its first quarter results, reporting revenue of $1.5 billion, or 44 cents per share, contrast to revenue of $1.46 billion, or 36 cents per share in the same quarter last year. Overall, this was a 19% enhance in profits.
Fifth Third Bancorp operates as a diversified financial services company in the United States. It operates through four segments: Commercial Banking, Branch Banking, Consumer Lending, and Investment Advisors.
At the end of Tuesday’s trade, Shares of Endo International plc (NASDAQ:ENDP), gained 2.80% to $83.03.
Endo Pharmaceuticals Inc., a partner of Endo International supports efforts to bring the medical community the first ever treatment guidelines for Peyronie’s Disease (PD), a condition in which collagen plaque, or scar tissue, develops on the shaft of the penis, and may harden and reduce flexibility. The company also declared recently that it has presented encore data at a key medical meeting evaluating the efficacy of XIAFLEX® (collagenase clostridium histolyticum) treatment for PD in addition to the impact of PD on erectile dysfunction (ED) and female partners.
The new guidelines, presented on Monday by the American Urological Association (AUA) at its 110th Annual Scientific Meeting in New Orleans, recommend the use of XIAFLEX® in combination with modeling in patients with stable PD, penile curvature greater than 30 degrees and less than 90 degrees, and intact erectile function. XIAFLEX®, which is the only treatment approved by the U.S. Food and Drug Administration for PD, received a stronger recommendation than any other potential treatment option for PD, based on the strength of existing data. XIAFLEX® is indicated for adult men with PD who have a plaque that can be felt and a curve in their penis greater than 30 degrees when treatment is started.
Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals.
Finally, Hilton Worldwide Holdings Inc. (NYSE:HLT), ended its last trade with 0.27% gain, and closed at $29.59.
Hilton Worldwide, declared a re-branding of Embassy Suites Hotels and Hampton Hotels in the U.S., adding the “by Hilton” endorsement to their monikers. The new brand logos and names, Embassy Suites by Hilton and Hampton by Hilton, represent the next phase of a renewed business strategy to further reinforce the brands’ identities within the Hilton Worldwide portfolio and the company’s continued commitment to the future growth, expansion, and evolution of its brands. The phased rollout starts this quarter and will bring about greater consistency as these brands already carry the ‘by Hilton’ endorsement outside of the U.S.
“The Hilton brand symbolizes quality, consistency, and familiarity, providing further reassurance to guests and owners alike,” said Jim Holthouser, executive vice president, global brands, Hilton Worldwide. “Research and historical brand data indicate that guests are more likely to stay at a ‘by Hilton’ hotel, and we are confident that this simple global modification to the Embassy Suites and Hampton brands will have a positive impact on brand performance for owners, developers, and franchisees in addition to consumers.”
Hilton Worldwide Holdings Inc., a hospitality company, owns, leases, manages, develops, and franchises hotels, resorts, and timeshare properties worldwide. The company operates hotels under 12 brand names, counting Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Curio - A Collection by Hilton, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton, and Hilton Grand Vacations.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
